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Aim To evaluate the relationship between sex, age and outcome in dilated cardiomyopathy (DCM).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methods
and results
We used proportional hazard modelling to examine the association between sex, age and all-cause mortality in
consecutive patients with DCM. Overall, 881 patients (290 women, median age 52 years) were followed for a median
of 4.9 years. Women were more likely to present with heart failure (64.0% vs. 54.5%; P = 0.007) and had more severe
symptoms (P < 0.0001) compared to men. Women had smaller left ventricular end-diastolic volume (125mL/m2 vs.
135mL/m2; P < 0.001), higher left ventricular ejection fraction (40.2% vs. 37.9%; P = 0.019) and were less likely to
have mid-wall late gadolinium enhancement (23.0% vs. 38.9%; P < 0.0001). During follow-up, 149 (16.9%) patients
died, including 41 (4.7%) who died suddenly. After adjustment, all-cause mortality [hazard ratio (HR) 0.61, 95%
confidence interval (CI) 0.41–0.92; P = 0.018] was lower in women, with similar trends for cardiovascular (HR 0.60,
95% CI 0.35–1.05; P = 0.07), non-sudden (HR 0.63, 95% CI 0.39–1.02; P = 0.06) and sudden death (HR 0.70, 95%
CI 0.30–1.63; P = 0.41). All-cause mortality (per 10 years: HR 1.36, 95% CI 1.20–1.55; P < 0.0001) and non-sudden
death (per 10 years: HR 1.51, 95% CI 1.26–1.82; P < 0.00001) increased with age. Cumulative incidence curves
confirmed favourable outcomes, particularly in women and those <60 years. Increased all-cause mortality in patients
>60 years of age was driven by non-sudden death.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Conclusion Women with DCM have better survival compared to men, which may partly be due to less severe left ventricular
dysfunction and a smaller scar burden. There is increased mortality driven by non-sudden death in patients >60 years
of age that is less marked in women. Outcomes with contemporary treatment were favourable, with a low incidence
of sudden death.
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Introduction
Dilated cardiomyopathy (DCM) is a heterogeneous condition man-
ifest in a diverse group of patients due to a combination of underly-
ing genetic susceptibility and environmental insults.1 The prognosis
of many patients with DCM remains poor and more precise risk
stratification and personalised therapy may considerably improve
outcomes. Sex and age are two simple, universally available patient
characteristics that deserve consideration.
Data from large registries suggest that women with heart fail-
ure (HF) have better transplant-free survival compared to men.2
Whether this relates to a higher proportion of non-ischaemic HF
in women or whether this is independent of aetiology remains
controversial.3 DCM is known to affect men more commonly than
women, however detailed data comparing differences in disease
phenotype, severity and outcome between sexes are lacking.4
The DANISH (Danish Study to Assess the Efficacy of ICDs in
Patients with Non-ischemic Systolic Heart Failure on Mortality)
found that implantation of a cardioverter-defibrillator (ICD) did
not reduce overall mortality.5 Whilst meta-analyses of trials have
suggested mortality benefit with ICD implantation, many of the
patients in these studies were not treated with contemporary HF
therapy, known to reduce sudden death.6,7 More precise selection
of patients with DCM for ICD is required. Subgroup analysis of the
DANISH demonstrated a mortality benefit with ICD implantation
in patients aged <59 years and a trend towards worse outcomes in
those >68 years. The explanation for these findings is unclear but a
higher rate of death from competing causes later in life may dilute
the benefit of an ICD.8 It is possible that malignant arrhythmia in
older patients signals advanced disease and a poor prognosis from
competing causes that cannot be improved by ICD implantation.
Equally, it is possible that those presenting later in life have a lower
incidence of ventricular arrhythmias.9 Examining the rates of death
from non-sudden and sudden causes according to sex and age could
help inform management strategy.
Methods
Consecutive patients with suspected DCM referred to our adult car-
diomyopathy service or for cardiovascular magnetic resonance (CMR)
between 2000 and 2011 were screened. The study complied with
the Declaration of Helsinki, was approved by the National Research
Ethics Service and participants entered in the registry provided written
informed consent (Figure 1). The final registry of 881 patients included
472 previously reported cases who underwent extended follow-up for
the purpose of this report.10 All patients underwent CMR at base-
line using a standardized protocol for image acquisition and analysis,
as previously described.11 The inclusion criterion was a diagnosis of
DCM,12 based on reduced left ventricular ejection fraction (LVEF) and
elevated left ventricular end-diastolic volume indexed to body surface
area (LVEDVi) compared to published age- and sex-specific reference
values.13 Exclusion criteria (Figure 1) included ischaemic heart disease
defined as a> 50% stenosis in a major coronary artery, evidence of
inducible ischaemia on functional testing, or infarct late gadolinium
enhancement (LGE) patterns on CMR. In addition, ischaemic heart
disease was excluded by invasive coronary angiography in 78.4%. A
further 7.1% had functional imaging without evidence of inducible ..
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.. ischaemia. Of the remaining patients (of whom 41.1% women), none
had angina, all were considered to be at low risk of coronary artery
disease by their attending physicians and the majority (n = 82; 9.2%)
were aged <40 years; accordingly, coronary angiography was not
performed.14
Patient follow-up was performed using postal questionnaires, tele-
phone interview and by accessing information from general practition-
ers, cardiologists and hospital notes. Deaths were identified through
the UKHealth and Social Care Information Service. Follow-up duration
was measured from the CMR scan until last confirmed contact with
the patient or the date of death. The primary endpoint was all-cause
mortality. Secondary endpoints were cardiovascular, non-sudden and
sudden cardiac death. The cause of death was confirmed by a commit-
tee of cardiologists using medical records, post-mortem results and
death certificates in line with guidance.15 Sudden death was defined as
‘unexpected death either within 1 h of the onset of cardiac symptoms
in the absence of progressive cardiac deterioration; during sleep; or
within 24 h of last being seen alive’.15
Statistical analysis
Baseline characteristics were compared between men and women and
those aged above or below 60 years of age using the Mann–Whitney
U test for continuous data and the Fisher’s exact test for categorical
data. Associations between age (as a continuous variable) and sex
and each endpoint were examined using univariable and multivariable
proportional hazard modelling. Multivariable analyses were adjusted for
important prognostic baseline covariates including age, sex, LVEF, New
York Heart Association (NYHA) functional class, left bundle branch
block (LBBB), atrial fibrillation (AF), smoking status and the presence
or absence of mid-wall LGE on CMR, as well as the presence or absence
of an ICD or cardiac resynchronisation therapy (CRT) device as a
time-varying covariate. Cumulative incidence curves were generated
for endpoints with event times measured from the baseline CMR date
for up to 10 years.
Results
The study population included 881 patients. The median age was
52 (interquartile range: 42–63) years, the median LVEF was 39%
and 290 (32.9%) were women.
Sex-based differences in baseline
characteristics and disease phenotype
Baseline characteristics are presented in Table 1. Women were
less likely to have a history of AF (P < 0.0001) and alcohol excess
(P < 0.0001) and more likely to have LBBB (P < 0.0001) and a his-
tory of previous chemotherapy (P < 0.0001) compared to men.
In addition, 18 (6.2%) women had a presentation in the peripar-
tum period. There was a trend towards women more frequently
having a family history of DCM compared to men (P = 0.054).
Three patients, one women and two men, were known to have
a pathogenic or likely pathogenic mutation in LMNA. HF was
more likely to be the presenting indication in women compared
to men (64.1% vs. 54.5%; P = 0.007) whilst a greater propor-
tion of men (22.0% vs. 13.8%) were referred after presenting
with arrhythmia (P = 0.004). In keeping with this, NYHA class was
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Identification, inclusion and exclusion of patients from the study cohort. CAD, coronary artery disease; CMR, cardiovascular
magnetic resonance; LGE, late gadolinium enhancement; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction.
worse in women compared to men (P < 0.0001). However, on
CMR, women had smaller LVEDVi (P < 0.001), indexed right ven-
tricular end-diastolic volumes (P < 0.0001) and indexed left atrial
volume (LAVi; P < 0.0001), higher LVEF (P = 0.019) and right ven-
tricular ejection fraction (P < 0.0001) and a lower prevalence of
mid-wall LGE (P < 0.0001). The results remained qualitatively the
same after indexing values using height rather than body surface
area. Apart from a higher prescription rate of angiotensin recep-
tor blockers in women compared to men (P = 0.04), pharmaco-
logical therapies for HF were similar between sexes (Table 2). In
addition, there were no significant differences in prescribed thera-
pies between sexes when patients with LVEF ≤40% were analysed
individually.
Age-based differences in baseline
characteristics and disease phenotype
Patients aged ≥60 years had worse NYHA class (P = 0.001), were
more likely to be prescribed loop diuretics (P = 0.0001) and had
higher systolic blood pressures (P < 0.001). There was also a lower
prescription of beta-blockers (P = 0.05) and mineralocorticoid
receptor antagonists (P = 0.01) to patients with a LVEF <40%
who were over 60 years of age (Table 2). Those over 60 years of
age were also more likely to have a history of AF (P < 0.0001), ..
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. hypertension (P < 0.0001) and LBBB (P < 0.0001) but less likely
to have a family history of DCM (P < 0.001) or to be referred
in the context of family screening (P < 0.001). On CMR, those
aged >60 years had lower LVEF (P < 0.001) and greater LAVi
(P < 0.001).
Primary and secondary endpoints
During follow-up, 149 (16.9%) patients died, 99 (11.2%) due to
cardiovascular causes (including 50 HF and 41 sudden deaths) and
a further 50 (5.7%) due to non-cardiovascular causes (including
cancer, sepsis, lung disease, gastrointestinal haemorrhage, massive
haemoptysis and small bowel obstruction). Rate of events per 100
patient-years by sex and age are included in Table 3.
Association between sex and outcome
All-cause mortality [hazard ratio (HR) 0.64, 95% confidence
interval (CI) 0.44–0.94; P = 0.020] and cardiovascular death (HR
0.58, 95% CI 0.36–0.93; P = 0.025) were lower in women com-
pared to men with similar trends for non-sudden (HR 0.68, 95%
CI 0.44–1.05; P = 0.088) and sudden death (HR 0.58, 95% CI
0.28-1.21; P = 0.15) (Figure 2 and Table 4). Following adjustment
for age, LVEF, NYHA class, AF, LBBB, smoking status, LGE and
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Baseline characteristics
Sex Age
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Men (n = 591) Women (n = 290) P-value <60 (n = 597) ≥60 (n = 284) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age (years) 52 (14.8) 53 (15.1) 0.099 44 (10.8) 69 (6.1) –
Male gender – – – 418 (70.0) 173 (60.9) 0.009
Body surface area (m2) 2.05 (0.20) 1.77 (0.19) <0.0001 1.97 (0.24) 1.92 (0.22) 0.006
Heart rate (b.p.m.) 72.7 (14.4) 74.0 (14.2) 0.079 73.1 (14.4) 73.1 (14.4) 0.96
SBP (mmHg) 120.2 (17.3) 120.2 (18.0) 0.89 118.3 (17.3) 124.2 (17.4) <0.0001
DBP (mmHg) 72.9 (10.9) 71.4 (10.4) 0.041 71.9 (11.0) 73.4 (10.4) 0.072
Smoker 117 (19.8) 32 (11.0) 0.001 122 (20.4) 27 (9.5) <0.0001
Alcohol excess 97 (16.4) 5 (1.7) <0.0001 76 (12.7) 26 (9.2) 0.14
Atrial fibrillation/flutter 140 (23.7) 28 (10.0) <0.0001 86 (14.4) 82 (27.9) <0.0001
Hypertension 123 (20.8) 68 (23.4) 0.38 99 (16.6) 92 (32.4) <0.0001
Diabetes mellitus 50 (8.5) 27 (9.3) 0.70 44 (7.4) 33 (11.6) 0.041
Hypercholesterolaemia 124 (21.0) 55 (19.0) 0.53 92 (15.4) 87 (30.6) <0.0001
Cerebrovascular accident 8 (1.3) 3 (1.1) 1.00 6 (1.0) 5 (1.7) 0.52
Family history of DCM 50 (8.5) 37 (12.8) 0.054 73 (12.3) 14 (4.9) <0.001
Family history of SCD 39 (6.6) 24 (8.3) 0.40 48 (8.1) 15 (5.3) 0.16
Previous chemotherapy 28 (9.7) 6 (1.0) <0.0001 18 (3.0) 16 (5.6) 0.01
Peripartum presentation 0 (0) 18 (6.2) <0.0001 18 (3.0) 0 (0) <0.0001
Neuromuscular disease 7 (1.2) 1 (0.3) 0.21 8 (1.3) 0 (0) 0.044
Left bundle branch block 134 (22.7) 124 (42.9) <0.0001 140 (23.5) 118 (41.8) <0.0001
NYHA class <0.0001 0.001
I 267 (45.3) 88 (30.8) 263 (44.1) 92 (32.9)
II 231 (39.2) 125 (43.7) 219 (36.7) 137 (48.9)
III/IV 92 (15.6) 73 (25.5) 114 (19.1) 51 (18.2)
Indications
Heart failure 322 (54.5) 186 (64.1) 0.007 346 (57.9) 162 (57.0) 0.83
Arrhythmic 130 (22.0) 40 (13.8) 0.004 116 (19.4) 54 (19.0) 0.93
Family screening 25 (4.2) 15 (3.4) 0.61 38 (6.3) 2 (0.7) <0.0001
Other 114 (19.2) 49 (16.9) 0.41 120 (20.1) 43 (15.1) 0.08
CMR measurements
LVEDViBSA (mL/m2) 135.4 (43.3) 125.3 (35.2) <0.001 132.2 (42.1) 131.8 (39.0) 0.81
LVEDViheight (mL/m) 154.9 (50.3) 135.4 (38.1) <0.0001 149.9 (50.2) 145.6 (41.4) 0.54
LVEF (%) 37.9 (12.9) 40.2 (12.0) 0.019 39.1 (13.0) 37.5 (11.8) 0.025
LV mass indexBSA (g/m2) 100.1 (27.9) 87.9 (25.6) <0.0001 95.6 (27.9) 97.2 (27.3) 0.33
LV mass indexheight (g/m) 115.1 (34.2) 95.2 (28.2) <0.0001 109.0 (35.1) 107.9 (30.6) 0.91
RVEDViBSA (mL/m2) 94.5 (27.0) 79.1 (21.1) <0.0001 92.5 (26.0) 83.2 (25.7) <0.0001
RVEDViheight (mL/m) 108.2 (31.0) 86.3 (24.6) <0.0001 105.0 (30.9) 92.8 (29.1) <0.0001
RVEF (%) 48.9 (13.6) 55.4 (14.9) <0.0001 50.0 (14.4) 53.3 (13.9) 0.003
LAViBSA (mL/m2) 68.6 (26.9) 61.0 (24.0) <0.0001 64.1 (24.3) 70.3 (29.5) 0.001
LAViheight (mL/m) 78.6 (31.1) 65.9 (25.6) <0.0001 72.7 (28.2) 78.4 (33.3) 0.014
LGE (presence) 229 (38.9) 66 (23.0) <0.0001 189 (31.9) 106 (37.5) 0.11
BSA, body surface area; CMR, cardiovascular magnetic resonance; DBP, diastolic blood pressure; DCM, dilated cardiomyopathy; LAVi, indexed left atrial volume; LGE, late
gadolinium enhancement; LV, left ventricular; LVEDVi, indexed left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESVi, indexed left ventricular
end-systolic volume; NYHA, New York Heart Association; RVEDVi, indexed right ventricular end-diastolic volume; RVEF, right ventricular ejection fraction; RVESVi, indexed
right ventricular end-systolic volume; SBP, systolic blood pressure; SCD, sudden cardiac death.
CRT or ICD implantation, all cause-mortality (HR 0.61, 95% CI
0.41–0.92; P = 0.018) was lower in women compared to men
with similar trends for cardiovascular (HR 0.60, 95% CI 0.35–1.05;
P = 0.07) and non-sudden death (HR 0.63, 95% CI 0.39–1.02;
P = 0.06) (Figure 2 and Table 4). Trends were similar in patients
with LVEF <40% and those with LVEF ≥40% (online supplemen-
tary Table S1). During follow-up, of those with a LVEF ≤35% at
baseline, 32 (32.3%) women and 99 (38.8%) men underwent ICD .
..
..
..
..
..
..
..
..
..
..
.. implantation (P = 0.27). Of those with a LVEF ≤35% and LBBB at
baseline, 37 (74.0%) women and 43 (59.7%) men received CRT
(P = 0.12). Women with LBBB had lower mortality compared to
men with LBBB (HR 0.39, 95% CI 0.20–0.78; P = 0.008). This was
not significantly different from the HR for women without LBBB
compared to men without LBBB (HR 0.81, 95% CI 0.52–1.26;
P = 0.35; heterogeneity P = 0.086). Of those with an ICD, the rate
of appropriate shocks was similar for women and men (HR 0.94,
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Prescribed medical therapies at baseline based on age, sex and left ventricular ejection fraction
All LVEF≤ 40%
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Men
(n = 591)
Women
(n = 290)
P-value Men
(n = 322)
Women
(n = 132)
P-value Men
(n = 269)
Women
(n = 158)
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Beta-blocker 433 (73.4) 209 (72.1) 0.69 266 (82.6) 100 (75.8) 0.12 167 (62.1) 109 (69.0) 0.17
ACE inhibitor 433 (73.3) 198 (68.3) 0.13 254 (78.9) 94 (71.2) 0.09 179 (66.5) 104 (65.8) 0.92
ARB 109 (18.5) 71 (24.5) 0.041 59 (18.3) 33 (25.0) 0.12 50 (18.6) 38 (24.1) 0.22
MRA 195 (33.0) 108 (37.4) 0.2 147 (45.7) 68 (51.5) 0.26 48 (36.4) 40 (25.3) 0.08
Loop diuretic 262 (44.3) 125 (43.1) 0.77 201 (62.4) 90 (68.2) 0.28 61 (22.7) 35 (22.2) 1.0
All LVEF≤ 40% LVEF> 40%
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
<60
(n = 597)
≥60
(n = 284)
P-value <60
(n = 295)
≥60
(n = 159)
P-value <60
(n = 302)
≥60
(n = 125)
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Beta-blocker 435 (72.9) 207 (73.1) 1.0 246 (83.4) 120 (75.5) 0.05 189 (62.6) 87 (69.6) 0.18
ACE inhibitor 429 (71.9) 202 (71.1) 0.87 225 (76.3) 123 (77.4) 0.82 204 (67.5) 79 (63.2) 0.43
ARB 113 (19.0) 67 (23.7) 0.11 63 (21.4) 29 (18.2) 0.46 50 (16.6) 38 (30.4) 0.002
MRA 208 (34.9) 95 (33.5) 0.7 153 (51.9) 62 (39.0) 0.01 55 (18.2) 33 (26.4) 0.07
Loop diuretic 233 (39.0) 154 (54.2) <0.0001 182 (61.7) 109 (68.6) 0.15 51 (16.9) 45 (36.0) 0.0001
ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist.
Table 3 Rate of events per 100 patient-years by sex and age group
Rate per 100 patient-years (95% CI)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Men (n = 591) Women (n = 290) <60 years (n = 597) ≥60 years (n = 284)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
All-cause mortality 3.6 (3.0–4.3) 2.3 (1.7–3.2) 2.4 (1.9–3.0) 4.9 (3.9–6.2)
Cardiovascular 2.5 (2.0–3.1) 1.4 (0.9–2.1) 1.8 (1.4–2.3) 2.8 (2.1–3.8)
Non-sudden death 2.6 (2.1–3.2) 1.7 (1.2–2.5) 1.5 (1.2–2.0) 4.1 (3.2–5.3)
Sudden cardiac death 1.0 (0.7–1.4) 0.6 (0.3–1.1) 0.9 (0.6–1.3) 0.8 (0.5–1.5)
CI, confidence interval.
95% CI 0.47–1.89; P = 0.86). Of those without an ICD, women
tended to be less prone to sudden death than men but this did
not achieve statistical significance (HR 0.60, 95% CI 0.29–1.27;
P = 0.18).
Association between age and outcome
All-cause mortality increased with age (per 10 years: HR 1.32, 95%
CI 1.17–1.48; P < 0.00001), largely driven by a rise in the rate
of death from non-sudden causes (per 10 years: HR 1.51, 95%
CI 1.29–1.78; P < 0.00001) (Figure 2 and Table 4). Death from
cardiovascular (HR 1.12, 95% CI 0.95–1.31; P = 0.18) and sudden
causes (per 10 years: HR 0.92, 95% CI 0.73–1.15; P = 0.47) did
not significantly change with advancing age. Results were similar in
univariable and multivariable analyses (Figure 2 and Table 4). Trends
were similar in patients with LVEF<40% and those with LVEF≥40%
(online supplementary Table S1). During follow-up, of those with a
LVEF≤35% at baseline, 86 (39.1%) of those<60 years of age and 45
(36.3%) of those older underwent ICD implantation (P = 0.91). Of
those with a LVEF ≤35% and LBBB at baseline, 46 (70.8%) of those .
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.. <60 years of age underwent CRT compared to 34 (59.6%) of those
older (P = 0.25). Of those with an ICD, there was no difference in
the rate of appropriate shocks with advancing age (per 10 years:
HR 0.89, 95% CI 0.71–1.11; P = 0.30). Of those without an ICD,
there was no difference in the rate of sudden death between those
aged >60 years compared to younger patients (per 10 years: HR
0.90, 95% CI 0.72–1.12; P = 0.35).
In keeping with the proportional hazard analysis, cumulative
incidence curves demonstrated increased all-cause mortality in
patients over 60 years of age compared to those younger that
was driven by death from non-sudden causes, without a similar
rise in sudden death (Figure 3). The rise in all-cause mortality and
non-sudden death was less marked in women compared to men.
In women under the age of 60 years, 5-year mortality estimates
from Kaplan–Meier curves was 6.7% (95% CI 3.7–11.8) compared
to 11.9% (95% CI 6.7–21.0) in those older. In men under the
age of 60 years, 5-year mortality estimates from Kaplan–Meier
curves was 13.5% (95% CI 10.3–17.5) compared to 24.4% (95%
CI 18.3–32.2) in those older.
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Figure 2 Forest plots demonstrating unadjusted and adjusted hazard ratios for the primary and secondary endpoints stratified by sex and
age. CV, cardiovascular; SCD, sudden cardiac death.
Table 4 Univariable and multivariable analyses for the primary and secondary endpoints
All-cause mortality Cardiovascular death Non-sudden death Sudden cardiac death
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HR for women vs.
men
Univariable 0.64 (0.44–0.94) 0.020 0.58 (0.36–0.93) 0.025 0.68 (0.44–1.05) 0.088 0.58 (0.28–1.21) 0.15
Multivariable* 0.61 (0.41–0.92) 0.018 0.60 (0.35–1.05) 0.074 0.63 (0.39–1.02) 0.060 0.70 (0.30–1.63) 0.41
HR based on age
(per 10 years
increase)
Univariable 1.32 (1.17–1.48) <0.00001 1.12 (0.95–1.31) 0.18 1.51 (1.29–1.78) <0.00001 0.92 (0.73–1.15) 0.47
Multivariable† 1.36 (1.20–1.55) <0.0001 1.16 (0.98–1.37) 0.078 1.51 (1.26–1.82) <0.00001 0.99 (0.78–1.24) 0.90
CI, confidence interval; HR, hazard ratio.
*Adjusted for left ventricular ejection fraction, New York Heart Association class, atrial fibrillation, left bundle branch block, smoking, the presence of late gadolinium
enhancement, age and the presence of an implantable cardioverter-defibrillator or cardiac resynchronisation therapy as time varying covariates.
†Adjusted for left ventricular ejection fraction, New York Heart Association class, atrial fibrillation, left bundle branch block, smoking, the presence of late gadolinium
enhancement, sex and the presence of an implantable cardioverter-defibrillator or cardiac resynchronisation therapy as time varying covariates.
Discussion
This is the first study to specifically examine the impact of sex
and age on the phenotype and outcome of DCM in a well char-
acterised population. Outcomes with contemporary treatment
were favourable. Overall, women had lower mortality than men
even after adjusting for several key prognostic variables, including
implanted devices. For example, women under the age of 60 years
had an estimated 5-year mortality rate of only 6.7% compared to
13.5% in men under 60 years of age. Sudden death accounted for
only 27.5% of overall mortality, in keeping with recent data from
Shen and colleagues demonstrating a reduction in this mode of
death with current HF therapy.16 The slightly higher rate of CRT
amongst women, reflecting the higher prevalence of LBBB, did not
account for the sex differences in outcome. Interestingly, women
had more severe symptoms despite having less severe cardiac .
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..
..
.. dysfunction, lower burden of scar and similar pharmacological ther-
apy compared to men. Our data also show that mortality is higher
in patients over 60 years of age and that this is predominantly driven
by death from non-sudden causes rather than sudden death.
A detailed description of differences in the outcome of men and
women in a broad well characterised DCM population has been
lacking until now. For patients with HF of mixed aetiology, several
studies have reported a lower mortality amongst women compared
to men but this may reflect the higher prevalence of coronary
artery disease amongst men, which carries a worse prognosis.3
Studies in patients with DCM secondary to specific genetic muta-
tions also suggest that men have a worse prognosis than women,
however, it has been unclear whether this is genotype-specific or
more general.17,18 Our study in patients with well characterised
DCM is not confounded by coronary artery disease or specific to
small subgroups with specific genetic causes.
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Figure 3 Cumulative incidence curves demonstrating the occurrence of endpoints based on the age and sex of patients. CV, cardiovascular.
This study offers several possible explanations for the better
prognosis amongst women with DCM including less severe cardiac
dysfunction and lower scar burden. Similar to previous multicentre
registries there was a predominance of men in our study, making up
almost 70% of the cohort.4 A greater susceptibility to developing
ventricular impairment in men may explain this disparity. Truncat-
ing mutations in titin are thought to make individuals susceptible
to developing contractile impairment and men with such variants
have been shown to have worse outcome than women.18 Protec-
tion from cardiovascular disease in pre-menopausal women has
been linked with sex hormones, including estradiol.19 In patients
with arrhythmogenic cardiomyopathy estradiol appears to have
a protective and testosterone a detrimental effect across both
sexes.20 Increased levels of estradiol reduced myocyte apopto-
sis in an in vitro model of arrhythmogenic cardiomyopathy, while
increased testosterone levels potentiated it. Myocyte death is cen-
tral to the development of replacement fibrosis and it is possible
that the different impact of these sex hormones on myocyte sur-
vival contributes to a higher prevalence of replacement fibrosis in
men. A sex disparity in the prevalence of replacement fibrosis in
DCM is consistent with other studies and has also been demon-
strated in acute myocarditis and aortic stenosis.21–23 Other studies
have demonstrated sex differences in gene expression in patients .
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. presenting with HF secondary to DCM and these may be respon-
sible for differences in phenotype and outcome.24
In our cohort, a greater percentage of women were referred
following a presentation with HF whilst an arrhythmic presentation
was more common in men. In keeping with this and similar to
previous studies in patients with HF, women reported more severe
functional limitation compared to men.2 Whether the greater
HF symptom burden in women is explained by differences in
pathophysiology, symptom reporting or perception is unclear. HF
secondary to diastolic dysfunction is more common in women3
but in our cohort, LAVi, a useful marker of chronically elevated
filling pressure, was smaller in women. Other markers of diastolic
function, exercise performance and natriuretic peptides were not
available for the current analysis but would provide interesting
insights.
Left bundle branch block was more common in women com-
pared to men. This observation is particularly interesting as LBBB
is often attributed to more advanced disease, however, in our study
women had other markers of less severe disease. Previous work in
patients receiving CRT demonstrated that LBBB is associated with
better survival in women compared to men, even when controlling
for co-morbidities.25 Our data also demonstrated greater survival
in women with LBBB compared to men with LBBB, despite similar
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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rates of CRT. The mechanism explaining the greater incidence of
LBBB in women and whether the prognostic significance of LBBB
differs between sexes merits further research.
Our study also suggests that caution should be exercised with
regard to the implantation of ICDs in patients over 60 years of age
due to an increased risk of death from competing causes, lending
support to the DANISH trial that demonstrated an absence of
overall survival benefit with ICD therapy in patients aged >59 years
and to data from previous clinical trials.5,8 Our data confirm that
the lack of survival benefit with ICD therapy in older patients is
because a high proportion of deaths are non-sudden rather than a
lower risk of arrhythmic death.
Limitations
This cohort, although large, was enrolled in a single centre and
has a relatively low prevalence of common co-morbidities such as
diabetes mellitus. It is possible that this reflects a degree of selec-
tion bias; however, our referral base is broad, from specialist and
non-specialist centres and the baseline characteristics are similar
to other cohorts.26 The referral characteristics and specifically the
proportion of men and women referred remain stable over the
study period (online supplementary Figure S1). This approach also
enables detailed CMR phenotyping using well established protocols
generating a well characterised population.
For some secondary endpoints, we had fewer events, limiting
statistical power. Differences in disease characteristics between
men and women may reflect differences in the time taken to seek
medical attention after the onset of symptoms. However, the differ-
ence in all-cause mortality persisted following adjustment for indi-
cators of disease severity at referral. Information on sex-specific
variables including obstetric history, use of hormone replacement
therapy or an oral contraceptive, age of menopause and previous
gynaecological surgery was not available.
We also recognise that a proportion of sudden deaths are likely
to relate to non-cardiac events such as aneurysmal rupture and
cerebral haemorrhage. In the absence of routine autopsy data,
assuming a cardiac aetiology to all sudden deaths could result in
over-estimation of the overall incidence of sudden cardiac death.
Nevertheless, in keeping with recent data, the incidence of sudden
death in our study was low.16
Conclusion
The prognosis of women with DCM is, on average, better
than for men. This may be partly attributed to a disease course
characterised by less severe ventricular dysfunction and a smaller
scar burden. The chance of death due to causes other than
arrhythmias increases with age, rendering ICDs less effective in
reducing all-cause mortality. Our data emphasise the importance of
developing sex- and age-specific risk stratification and management
approaches. ..
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Table S1. Univariable and multivariable analyses for the primary
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